Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

D Casabonne; Y Benavente; J Seifert; L Costas; M Armesto; M Arestin; C Besson; Fatemeh Saberi Hosnijeh; EJ Duell; E Weiderpass; G Masala; R Kaaks; F Canzian; MD Chirlaque; V Perduca; FR Mancini; V Pala; A Trichopoulou; A Karakatsani; C La Vecchia; MJ Sánchez; R Tumino; MJ Gunter; P Amiano; S Panico; C Sacerdote; JA Schmidt; H Boeing; MB Schulze; A Barricarte; E Riboli; A Olsen; A Tjønneland; R Vermeulen; A Nieters; CH Lawrie; S de Sanjosé

doi:10.1002/ijc.32894

Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

D Casabonne, Y Benavente, J Seifert, L Costas, M Armesto, M Arestin, C Besson, Fatemeh Saberi Hosnijeh, EJ Duell, E Weiderpass, G Masala, R Kaaks, F Canzian, MD Chirlaque, V Perduca, FR Mancini, V Pala, A Trichopoulou, A Karakatsani, C La VecchiaMJ Sánchez, R Tumino, MJ Gunter, P Amiano, S Panico, C Sacerdote, JA Schmidt, H Boeing, MB Schulze, A Barricarte, E Riboli, A Olsen, A Tjønneland, R Vermeulen, A Nieters, CH Lawrie, S de Sanjosé

Immunology

Research output: Contribution to journal › Article › Academic › peer-review

31 Citations (Scopus)

Original language	English
Pages (from-to)	1315-1324
Number of pages	10
Journal	International Journal of Cancer
Volume	147
Issue number	5
DOIs	https://doi.org/10.1002/ijc.32894
Publication status	Published - 2020

Research programs

EMC MM-02-72-02
EMC OR-01

Access to Document

10.1002/ijc.32894

Cite this

Casabonne, D., Benavente, Y., Seifert, J., Costas, L., Armesto, M., Arestin, M., Besson, C., Saberi Hosnijeh, F., Duell, EJ., Weiderpass, E., Masala, G., Kaaks, R., Canzian, F., Chirlaque, MD., Perduca, V., Mancini, FR., Pala, V., Trichopoulou, A., Karakatsani, A., ... de Sanjosé, S. (2020). Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study. International Journal of Cancer, 147(5), 1315-1324. https://doi.org/10.1002/ijc.32894

@article{f2daa7ae47dd4b7ba810fbed2edfc2a6,

title = "Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study",

author = "D Casabonne and Y Benavente and J Seifert and L Costas and M Armesto and M Arestin and C Besson and \{Saberi Hosnijeh\}, Fatemeh and EJ Duell and E Weiderpass and G Masala and R Kaaks and F Canzian and MD Chirlaque and V Perduca and FR Mancini and V Pala and A Trichopoulou and A Karakatsani and \{La Vecchia\}, C and MJ S{\'a}nchez and R Tumino and MJ Gunter and P Amiano and S Panico and C Sacerdote and JA Schmidt and H Boeing and MB Schulze and A Barricarte and E Riboli and A Olsen and A Tj{\o}nneland and R Vermeulen and A Nieters and CH Lawrie and \{de Sanjos{\'e}\}, S",

year = "2020",

doi = "10.1002/ijc.32894",

language = "English",

volume = "147",

pages = "1315--1324",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "John Wiley \& Sons Inc.",

number = "5",

}

Casabonne, D, Benavente, Y, Seifert, J, Costas, L, Armesto, M, Arestin, M, Besson, C, Saberi Hosnijeh, F, Duell, EJ, Weiderpass, E, Masala, G, Kaaks, R, Canzian, F, Chirlaque, MD, Perduca, V, Mancini, FR, Pala, V, Trichopoulou, A, Karakatsani, A, La Vecchia, C, Sánchez, MJ, Tumino, R, Gunter, MJ, Amiano, P, Panico, S, Sacerdote, C, Schmidt, JA, Boeing, H, Schulze, MB, Barricarte, A, Riboli, E, Olsen, A, Tjønneland, A, Vermeulen, R, Nieters, A, Lawrie, CH & de Sanjosé, S 2020, 'Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study', International Journal of Cancer, vol. 147, no. 5, pp. 1315-1324. https://doi.org/10.1002/ijc.32894

Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study. / Casabonne, D; Benavente, Y; Seifert, J et al.
In: International Journal of Cancer, Vol. 147, No. 5, 2020, p. 1315-1324.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

AU - Casabonne, D

AU - Benavente, Y

AU - Seifert, J

AU - Costas, L

AU - Armesto, M

AU - Arestin, M

AU - Besson, C

AU - Saberi Hosnijeh, Fatemeh

AU - Duell, EJ

AU - Weiderpass, E

AU - Masala, G

AU - Kaaks, R

AU - Canzian, F

AU - Chirlaque, MD

AU - Perduca, V

AU - Mancini, FR

AU - Pala, V

AU - Trichopoulou, A

AU - Karakatsani, A

AU - La Vecchia, C

AU - Sánchez, MJ

AU - Tumino, R

AU - Gunter, MJ

AU - Amiano, P

AU - Panico, S

AU - Sacerdote, C

AU - Schmidt, JA

AU - Boeing, H

AU - Schulze, MB

AU - Barricarte, A

AU - Riboli, E

AU - Olsen, A

AU - Tjønneland, A

AU - Vermeulen, R

AU - Nieters, A

AU - Lawrie, CH

AU - de Sanjosé, S

PY - 2020

Y1 - 2020

U2 - 10.1002/ijc.32894

DO - 10.1002/ijc.32894

M3 - Article

C2 - 32012253

SN - 0020-7136

VL - 147

SP - 1315

EP - 1324

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - 5

ER -